Drug Trial Radar · NCT01447043
Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)
Last checked: Nov 20, 2026Latest source record: Jan 27, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,609
Actual
Start
Jan 2009
Primary completion
Aug 2011
Study completion Nov 2012
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Oct 5, 2011
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and August 31, 2009 must be consecutively screened and, if eligible, enrolled. Patients will be followed up at maximum until August 31, 2011. Switch to any other Anti vascUlar endothelial growth factor (anti VEGF) treatment will be documented and followed up. For each patient, demographics, medical history, administered treatments, results of ocular and visual assessments and other tests (where available) will be documented.
Conditions
- Ophthalmology, Macular Degeneration
Interventions
RanibizumabDrug
Patients with wet AMD treated with ranibizumab as prescribed by physician
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in visual acuity after start of Anti vascUlar endothelial growth factor (anti VEGF) therapy with ranibizumab, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or Snellen chardTime frame: Baseline and 24 months
Locations
10 sites in 10 countries. Site status is shown where the registry gives one.
Site not named
Many Locations, Australia
Site not named
Many Locations, Canada
Site not named
Many Locations, France
Site not named
Many Locations, Germany
Site not named
Many Locations, Ireland
Site not named
Many Locations, Italy
Site not named
Many Locations, Japan
Site not named
Many Locations, Netherlands
Site not named
Many Locations, United Kingdom
Site not named
Many Locations, Venezuela
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.